PURPOSE OF REVIEW Olfactory neuroblastoma (ONB) is a rare malignancy originating from olfactory neuroepithelial cells. Given its uncommon nature and complex clinical presentation, this comprehensive review highlights recent findings and treatment approaches for advancing clinical practice and research. RECENT FINDINGS Recent literature emphasizes significant advancements in the genomic profiling and molecular classification of ONB. Emerging targeted therapies include somatostatin analogs and programmed death-ligand 1 (PD-L1) inhibitors. In addition, the development of genetically engineered mouse models has provided valuable platforms for testing new treatment strategies, revealing similarities between ONB and small cell lung cancer, which may inform future therapeutic approaches. SUMMARY These findings have profound implications on clinical practice. Improved diagnostic accuracy through advanced imaging and genomic profiling in addition to identifying specific mutations for targeted therapy can lead to personalized treatments of patients with ONB. Developments in genetically engineered mouse models and multiinstitutional collaborative efforts are vital for advancing research and standardizing molecular testing. The integration of advanced imaging techniques, genomic profiling, and targeted therapies holds promise for improving patient outcomes and understanding this rare malignancy.

中文翻译：

---

嗅觉神经母细胞瘤研究的最新进展。


综述目的嗅觉神经母细胞瘤 （ONB） 是一种起源于嗅觉神经上皮细胞的罕见恶性肿瘤。鉴于其不常见的性质和复杂的临床表现，本综述重点介绍了最新的发现和治疗方法，以推进临床实践和研究。最近的发现最近的文献强调了 ONB 基因组分析和分子分类的重大进展。新兴的靶向治疗包括生长抑素类似物和程序性死亡配体 1 （PD-L1） 抑制剂。此外，基因工程小鼠模型的开发为测试新的治疗策略提供了有价值的平台，揭示了 ONB 和小细胞肺癌之间的相似性，这可能为未来的治疗方法提供信息。摘要 这些发现对临床实践具有深远的影响。除了识别靶向治疗的特定突变外，通过先进的成像和基因组分析提高诊断准确性，可以导致 ONB 患者的个性化治疗。基因工程小鼠模型的发展和多机构合作对于推进研究和分子检测标准化至关重要。先进成像技术、基因组分析和靶向治疗的整合有望改善患者预后和了解这种罕见的恶性肿瘤。